La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Emyria Gestion

Gestion contrôle des critères 2/4

Emyria's CEO is Michael Winlo, appointed in Nov 2019, has a tenure of 4.75 years. total yearly compensation is A$620.11K, comprised of 61.3% salary and 38.7% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth A$23.28K. The average tenure of the management team and the board of directors is 3.1 years and 3.5 years respectively.

Informations clés

Michael Winlo

Directeur général

AU$620.1k

Rémunération totale

Pourcentage du salaire du PDG	61.3%
Durée du mandat du directeur général	4.8yrs
Propriété du PDG	0.2%
Durée moyenne d'occupation des postes de direction	3.1yrs
Durée moyenne du mandat des membres du conseil d'administration	3.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Michael Winlo a-t-elle évolué par rapport aux bénéfices de Emyria?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$9m
Jun 30 2023	AU$620k	AU$380k	-AU$5m
Mar 31 2023	n/a	n/a	-AU$6m
Dec 31 2022	n/a	n/a	-AU$8m
Sep 30 2022	n/a	n/a	-AU$7m
Jun 30 2022	AU$615k	AU$486k	-AU$7m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$6m
Jun 30 2021	AU$471k	AU$350k	-AU$5m
Mar 31 2021	n/a	n/a	-AU$5m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$506k	AU$362k	-AU$5m

Rémunération vs marché: Michael's total compensation ($USD416.57K) is above average for companies of similar size in the Australian market ($USD299.11K).

Rémunération et revenus: Michael's compensation has increased whilst the company is unprofitable.

PDG

Michael Winlo

4.8yrs

Titularisation

AU$620,106

Compensation

Dr. Michael Winlo serves as Managing Director of Emyria Limited (formerly known as Emerald Clinics Limited) since November 26, 2019 and served as its Chief Executive Officer until November 26, 2019. Dr. Wi...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Michael Winlo	MD & Director	4.8yrs	AU$620.11k	0.16% A$ 23.3k
Alistair Vickery	Executive Medical Director & Director	5.4yrs	AU$385.39k	0.11% A$ 16.8k
Joseph Ohayon	Chief Financial Officer	no data	pas de données	pas de données
Sara Polanski	Communications & Brand Manager	1.2yrs	pas de données	pas de données
Tracie Ernenwein	Head of Research & Drug Development	no data	pas de données	pas de données
Mary-Ann Rennie	Head of Corporate Operations	no data	pas de données	pas de données
Susan Park	Company Secretary	1.4yrs	pas de données	pas de données

3.1yrs

Durée moyenne de l'emploi

Gestion expérimentée: EMD's management team is considered experienced (3.1 years average tenure).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Michael Winlo	MD & Director	4.8yrs	AU$620.11k	0.16% A$ 23.3k
Alistair Vickery	Executive Medical Director & Director	4.8yrs	AU$385.39k	0.11% A$ 16.8k
Henry Bosch	Member of Medical Advisory Board	no data	pas de données	pas de données
Greg Hutchinson	Independent Non-Executive Chairman	less than a year	pas de données	0.12% A$ 18.0k
John Tooke	Member of Medical Advisory Board & Independent Non-Executive Director	4.5yrs	AU$51.99k	pas de données
Mohit Kaushal	Non-Executive Director	less than a year	pas de données	pas de données
Karen Smith	Non-Executive Director & Chairman of Strategic Advisory Board	3.5yrs	AU$248.99k	0.15% A$ 22.8k
David Putrino	Member of Medical Advisory Board	no data	pas de données	pas de données
Nik Zeps	Member of Medical Advisory Board	no data	pas de données	pas de données
Philip Finch	Member of Medical Advisory Board	no data	pas de données	pas de données
Jennifer Morgan	Member of Medical Advisory Board	no data	pas de données	pas de données
Richard Magtengaard	Member of Medical Advisory Board	3.5yrs	pas de données	pas de données

3.5yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Conseil d'administration expérimenté: EMD's board of directors are considered experienced (3.5 years average tenure).

Emyria Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited, Annual General Meeting, Nov 16, 2023

Emyria Limited Announces Strategic Board Transition

Less than half of directors are independent

Emyria Limited, Annual General Meeting, Oct 25, 2022

Recent updates

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

New major risk - Financial position

New minor risk - Share price stability

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Emyria Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Emyria Limited Announces Strategic Board Transition

Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million.

Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients

Emyria Limited Expands MDMA Programs Following Landmark TGA Decision

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Its Acceptance into the Preclinical Screening Platform for Pain Program

Less than half of directors are independent

Emyria Limited and The University of Western Australia Expands Unique MDMA

Emyria Expands Clinical Sites for EMD-RX5 Phase 3 Trial

Emyria Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Emyria Limited Receives Ethics Approval for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Initiation of Human Cell-Line Preclinical Studies to Advance Its Mdma-Inspired Drug Discovery Partnership with the University of Western Australia

Emyria Limited Announces Positive Progress of its Preclinical MDMA Analogue Medicine Program

Emyria Limited Reports Positive Phase 1 Trial Data for EMD-RX5 Indicating Ideal Bioavailability, Safety and Tolerability Among 12 Healthy and Demographically Diverse Volunteer Subjects

We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely

Emyria Limited Receives Further Positive MDMA Analogue Screening Results

Less than half of directors are independent

Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial

Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial

Emyria Limited Commences for the EMD-RX5 Clinical Development Program

Emyria Limited Ethics Approval Receives for EMD-RX5 Phase 1 Study

Emyria Limited Announces Substantial Expansion of Proprietary MDMA Analogue Library Being Created with the University of Western Australia

Emyria Limited Announces Phase 1 Clinical Trials to Commence for Its Leading Ultra-Pure CBD Drug Candidate, Referred to as EMD-RX5

Emyria Limited announced that it expects to receive AUD 5 million in funding from Tattarang Pty Ltd

Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Limited Provides Novel Mdma Analogue Screening Program Advanced Update

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Executes Pure CBD Agreement with Altasciences to Accelerate FDA and TGA Cannabinoid Registration Programs

Emyria Advances EMD-004 Program Towards Registration

We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully

Emyria Limited and Mind Medicine Australia Launch MDMA-Assisted Therapy Program for PTSD

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Emyria Limited Announces the Appointment of Dr. Karen Smith to Chair the Company's Strategic Advisory Board

New 90-day high: AU$0.23

Emyria Limited Wins Digital Health Monitoring Grant with UWA

Emyria Limited Appoints Dr Richard Magtengaard, to Its Medical Advisory Board

Emyria Limited to Pursue Registration of EMD-003 with Australia's Therapeutic Goods Administration in 2021

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.

Emyria Limited Launches Drug Development Program Based on RWE

Emyria Limited Partners with Mind Medicine Australia

Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares

Executive Chairman recently bought AU$61k worth of stock

Emyria Limited Enters Data Deal with Zelira to Support Autism Trial

Zelira Therapeutics Ltd Enters into Agreement with Emyria Ltd

Emerald Clinics Limited to Report Fiscal Year 2020 Results on Oct 30, 2020

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi